Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind trial of tremelimumab versus placebo in unresectable pleural or peritoneal malignant mesothelioma (second- or third-line)
KCT0000961Phase 2Recruiting
- Sponsor
- MedImmune
- Start
- Apr 2014
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pleural mesothelioma and peritoneal mesothelioma comparing Tremelimumab with Placebo (2 arms). Started Apr 2014; status: recruiting.
02
Drugs
tremelimumab
03
Conditions
pleural mesotheliomaperitoneal mesothelioma
Beyond the preview
Go deeper on KCT0000961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000961.